Genmab (Otc) (GMAB) has released an update.
Genmab A/S is set to acquire ProfoundBio for $1.8 billion, aiming to enhance its oncology portfolio with ProfoundBio’s advanced antibody-drug conjugate (ADC) technology and a promising pipeline of cancer therapies. The deal will notably include rinatabart sesutecan (Rina-S), a next-generation ADC targeting ovarian cancer and other solid tumors, which has already earned Fast Track designation from the U.S. FDA. This strategic move is expected to bolster Genmab’s presence in gynecologic oncology and accelerate the development of innovative cancer treatments.
For further insights into GMAB stock, check out TipRanks’ Stock Analysis page.
